Claims for Patent: 8,852,240

Summary for Patent: 8,852,240

Title:	Methods and compositions for fostering and preserving bone growth
Abstract:	A method for augmenting bone in a subject in need thereof including installing within an interior portion of a bone located in the subject a sufficient amount of a biocompatible material to form a scaffold within the bone interior, wherein the scaffold serves as a support for the formation of new bone within the bone interior portion, and administering to the subject a sufficient amount of at least one bone augmentation agent to elevate blood concentration of at least one anabolic agent in the subject. The method may further include administering at least one anti-resorptive agent to the subject in an amount sufficient to substantially prevent resorption of new bone growth. In another embodiment, the method may further include a step of mechanically inducing an increase in osteoblast activity in the subject, wherein the elevation in blood concentration of the anabolic agent and the increase in osteoblast activity at least partially overlap in time.
Inventor(s):	Vignery; Agnes (Branford, CT), Mehta; Nozer M. (Randolph, NJ), Gilligan; James P. (Union, NJ), Murphy; Kieran P. (Baltimore, MD)
Assignee:	Kieran Murphy, LLC (Towson, MD) Yale University (New Haven, CT)
Application Number:	11/796,439
Patent Claims:	1. A method for augmenting bone in a subject in need thereof, said method comprising: (a) mechanically inducing an increase in osteoblast activity within said subject; (b) installing within an interior portion of a bone within said subject where the increase in osteoblast activity has been induced a sufficient amount of a biocompatible material to form a scaffold within said bone interior, said scaffold serving as a support for formation of new bone within said interior portion; and (c) separately administering to said subject, at a location other than into the bone, a sufficient amount of at least one bone augmentation agent to elevate blood concentration of at least one bone anabolic agent in said subject, wherein said bone augmentation agent is systematically administered at the location other than into the bone by a method selected from the group consisting of by injection, intravenously, peroral, transdermally, trans-nasally and transrectally, and wherein the elevation in blood concentration of the anabolic agent in said subject and the increase in osteoblast activity therein at least partially overlap in time. 2. The method according to claim 1, wherein the biocompatible material is selected from the group consisting of biologically active bone cements, bone morphogenic proteins, polymers, fibrinogen, synthetic fibrins, collagen gels, collagen with hydroxyapatite suspensions and combinations thereof. 3. The method according to claim 2, wherein the biocompatible material is a biologically active bone cement and the bone cement is selected from the group consisting of calcium phosphate, calcium hydroxyapatite, calcium sulphate and calcium aluminate. 4. The method according to claim 1, wherein the bone augmentation agent is a bone anabolic agent. 5. The method according to claim 4, wherein the bone anabolic agent is selected from the group consisting of a parathyroid hormone (PTH), anabolic Vitamin D analogs, a low-density lipoprotein receptor-related protein 5 (LRP5) activator, or an inhibitor of sclerostin binding to LRP5, an activator of non-genomic estrogen-like signaling (ANGELS), an insulin-like growth factor (IGF), a fibroblast growth factor (FGF), leptin, a prostaglandin, a statin, strontium, a growth hormone, a growth hormone releasing factor (GHRF), hepatocyte growth factor (HGF), calcitonin gene related peptide (CGRP), parathyroid hormone related peptide (PTHrP), transforming growth factor (TGF)-.beta.1 and combinations thereof. 6. The method according to claim 5, wherein the bone anabolic agent is a parathyroid hormone and said hormone is selected from the group consisting of a natural parathyroid hormone, a truncate of natural parathyroid hormone, an amidated truncate of natural parathyroid hormone, an amidated natural parathyroid hormone and combinations thereof. 7. The method according to claim 6, wherein a sufficient amount of said parathyroid hormone is administered to said subject to achieve a pulsatile blood concentration thereof in said subject of between about 50-350 pg/ml. 8. The method according to claim 6, wherein said sufficient amount of parathyroid hormone is from about 10 .mu.g-10 mg pure weight of PTH hormone per dose. 9. The method according to claim 6, wherein said parathyroid hormone is administered via injection and the sufficient amount of parathyroid hormone is from about 10-200 .mu.g per dose. 10. The method according to claim 6, wherein the bone anabolic agent is PTH[1-34] in the free acid form. 11. The method according to claim 6, wherein the bone anabolic agent is an amidated truncate of natural parathyroid hormone and said truncate is selected from the group consisting of PTH[1-30]NH2, PTH[1-31]NH2, PTH[1-32]NH2, PTH[1-33]NH2, PTH[1-34]NH2 and combinations thereof. 12. The method according to claim 1, wherein the bone augmentation agent is at least one agent that causes elevated levels of an endogenous anabolic agent within said subject. 13. The method according to claim 12, wherein the agent causing an increased expression of the endogenous bone anabolic agent within said subject is selected from the group consisting of caicilytic agents and antibodies to sclerostin. 14. The method according to claim 1, which further comprises administering to the subject an anti-resorption agent, said anti-resorptive agent being administered in an amount sufficient to substantially prevent resorption of said new bone growth. 15. The method according to claim 14, wherein the anti-resorptive agent is a bisphosphonate or a calcitonin selected from the group consisting of human calcitonin, salmon calcitonin, eel calcitonin, elkatonin, porcine calcitonin, chicken calcitonin, calcitonin gene related peptide (CGRP) and combinations thereof. 16. The method according to claim 15, wherein the antiresorptive agent is salmon calcitonin and wherein the salmon calcitonin is administered to said subject in an amount calculated to achieve a substantially continuous blood concentration thereof of between about 5-500 pg/ml. 17. The method according to claim 16, wherein the amount of salmon calcitonin is from about 5 .mu.g to 5 mg pure weight of the calcitonin per dose. 18. The method according to claim 16, wherein the salmon calcitonin is administered via injection and the amount of salmon calcitonin is from about 5 .mu.g-200 .mu.g per dose. 19. The method according to claim 1 wherein the bone augmentation agent is a parathyroid hormone and wherein blood concentration of the parathyroid hormone in said subject is raised to a level of between about 50-350 pg/ml by no later than 7 days following said mechanical inducement. 20. The method according to claim 1, additionally comprising forming a sufficient amount of additional bone in a jaw region of said subject to provide an anchor for a dental implant implanted into said jaw region. 21. The method according to claim 1, additionally comprising forming a sufficient amount of additional bone in one or more targeted bones of said subject to permit a prosthetic device implanted into at least one said targeted bone to be securely anchored thereto. 22. The method according to claim 1, additionally comprising forming a sufficient amount of additional bone in said subject to serve as a secure anchor for a hollow, adjustable insert anchored to said additional bone. 23. The method according to claim 1, which further comprises targeting at least one vertebra of said subject for additional bone formation and wherein a sufficient amount of bone is added to said at least one vertebra such that the subject is substantially freed from chronic pain caused due to vertebral crush. 24. The method according to claim 1, wherein additional bone is formed on at least one vertebra of said subject in an amount sufficient to stabilize said at least one vertebra due to strengthening thereof. 25. The method according to claim 1, wherein the biocompatible material is administered via an injection into a location selected from the group consisting of the proximal femoral, the hip, the distal radius, the proximal humerus, the calcaneus, the ribs, the tibia and the sacrum. 26. The method according to claim 1, wherein the bone augmentation agent is administered in a manner selected from the group consisting of orally, nasally, transdermally, rectally, subcutaneously and intravenously.

Details for Patent 8,852,240

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2024-10-25